1. Home
  2. LARK vs DTIL Comparison

LARK vs DTIL Comparison

Compare LARK & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

N/A

Current Price

$26.68

Market Cap

161.7M

Sector

Finance

ML Signal

N/A

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

HOLD

Current Price

$7.25

Market Cap

194.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LARK
DTIL
Founded
1885
2006
Country
United States
United States
Employees
283
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
161.7M
194.3M
IPO Year
2001
2019

Fundamental Metrics

Financial Performance
Metric
LARK
DTIL
Price
$26.68
$7.25
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$45.00
AVG Volume (30 Days)
3.2K
209.6K
Earning Date
04-29-2026
05-14-2026
Dividend Yield
3.07%
N/A
EPS Growth
35.84
N/A
EPS
3.07
N/A
Revenue
N/A
$1,070,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.43
$3.53
52 Week High
$30.85
$8.82

Technical Indicators

Market Signals
Indicator
LARK
DTIL
Relative Strength Index (RSI) 54.83 56.96
Support Level $27.01 $4.56
Resistance Level $28.93 $7.59
Average True Range (ATR) 0.64 0.45
MACD 0.01 -0.10
Stochastic Oscillator 45.69 38.69

Price Performance

Historical Comparison
LARK
DTIL

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Share on Social Networks: